(Q34625826)

3 August 2017

1 reference

title

New treatments for pulmonary arterial hypertension (English)

1 reference

3 August 2017

1 reference

Marius M Hoeper

1

1 reference

3 August 2017

Nazzareno Galiè

series ordinal

2

1 reference

3 August 2017

Gerald Simonneau

series ordinal

3

1 reference

3 August 2017

Lewis J Rubin

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

American Journal of Respiratory and Critical Care Medicine

3 August 2017

1 reference

3 August 2017

165

1 reference

3 August 2017

9

1 reference

3 August 2017

1209-1216

1 reference

Role of atrial septostomy in the treatment of pulmonary vascular disease

3 August 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Primary pulmonary hypertension: a vascular biology and translational research "Work in progress".

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

A new era in the treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Vascular endothelial growth factor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Genetic clues to the cause of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Prostaglandin I2 analogue, iloprost, down regulates mitogen-activated protein kinases of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

21 January 2018

Noninvasive Ventilation

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Long-term treatment of pulmonary hypertension with aerosolized iloprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Sildenafil modulates hemodynamics and pulmonary gas exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

The L-arginine-nitric oxide pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Viagra for impotence of pulmonary vasodilator therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200110-028PP

10.1164/RCCM.200110-028PP

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference